HCPLive

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Most Popular

Recommended Reading

Since physicians are unlikely to see many Opsoclonus Myoclonus Syndrome (OMS) patients, a Boston, MA team set out to offer clinical features, diagnostic findings and recommended treatments for this rare condition. It is often a sign of cancer.
Mammography screening is associated with considerable costs linked to false-positive mammograms and breast cancer overdiagnosis, with national expenditure estimated at $4 billion annually, according to a study published in the April issue of Health Affairs.

Although many women with breast cancer are concerned about their genetic risk for other cancers -- as well as their relatives' risk for breast cancer -- almost half of these patients don't get information about genetic testing, according to a study published online April 6 in the Journal of Clinical Oncology.

The risk of breast and ovarian cancer varies with the type and location of BRCA1/2 mutations, according to a study published in the April 7 issue of the Journal of the American Medical Association.

$vAR$